Reconsidering Japan's underperformance in pharmaceuticals: Evidence from Japan's anticancer drug sector

Enterprise and Society

Volumn 11, Issue 3, 2010, Pages 560-593

  Umemura, Maki ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CULTURAL FACTOR; DRUG INDUSTRY; DRUG THERAPY; ECONOMICS; EDUCATION; ETHNOLOGY; GOVERNMENT; HISTORY; HISTORY OF MEDICINE; JAPAN; LEGAL ASPECT; PHARMACOLOGY; POLICY; PUBLIC HEALTH;

CULTURAL CHARACTERISTICS; DRUG INDUSTRY; DRUG THERAPY; ECONOMICS; GOVERNMENT AGENCIES; HISTORY OF MEDICINE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; JAPAN; PHARMACOLOGY; PUBLIC HEALTH; PUBLIC POLICY;

EID: 77955909896     PISSN: 14672227     EISSN: 14672235     Source Type: Journal    
DOI: 10.1093/es/khq063     Document Type: Article

References (111)

1. Anchordoguy, Marie. Reprogramming Japan: The High Tech Crisis under Communitarian Capitalism. Ithaca, NY: Cornell University Press 2005.
2. Barral, P.E. 20 Years of Pharmaceutical Research Results throughout the World. Antony: Rhone-Poulenc Rorer Foundation, 1996.
3. Chandler, Alfred D. Shaping the Industrial Century: The Remarkable Story of the Modern Chemical and Pharmaceutical Industries. Cambridge, MA: Harvard University Press, 2005.
4. Coleman, Samuel. Japanese Science: From the Inside. London: Routledge, 1999.
5. Coley, Wiliam Bradley. The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas: With a Report of Ten Original Cases. Philadelphia: Lea Brothers, 1893.
6. Collins, Steven W. The Race to Commercialize Biotechnology: Molecules, Markets, and the State in the United States and Japan. London: Routledge-Curzon, 2004.
7. Datamonitor. "Chugai Pharmaceutical Co. Ltd." Company Profile. London: Datamonitor, 2007.
8. Dunn, Christopher. Scrip's 1994 Review of Cancer Chemotherapy. Richmond: PJB, 1994.
9. Hasegawa, Hisashi. Iyakuhin [Pharmaceuticals]. Tokyo: Nihon Keizai Hyornsha, 1989.
10. Howells, Jeremy, and Ian Neary. Intervention and Technological Innovation: Government and the Pharmaceutical Industry in the UK and Japan. Basingstoke: Macmillan, 1995.
11. Institute of Microbial Chemistry. Institute of Microbial Chemistry: 1962-1977. Tokyo: Center for Academic Publications, 1977.
12. Jih. Yakuji Handobukku [Pharmaceutical Affairs Handbook]. Tokyo: Jih 2000-2007.
13. Johnson, Chalmers A. MITI and the Japanese Miracle: The Growth of Industrial Policy, 1925-1975. Stanford, CA: Stanford University Press, 1982.
14. Japan Bioindustry Association. Baiobench Tkei Hkokusho 2005 [Statistical Report on Bioindustries]. Tokyo: Japan Bioindustry Association, 2006.
15. Kazis, Dimitris. Post-war Industrial Policy and the Electronics Industry in Japan. Athens: Centre of Planning and Economic Research, 1988.
16. Landau, Ralph, Basil Achilladelis, and Alexander Scriabine. eds. Pharmaceutical Innovation: Revolutionizing Human Health. Philadelphia: Chemical Heritage Press, 1999.
17. Life Insurance Association of Japan. Seimeihoken Jigy Gaiky [Summary of Life Insurance Business]. Tokyo: Life Insurance Association of Japan 1957- 2008.
18. Longe, Jacqueline, and Deirdre S. Blanchfield eds. The Gale Encyclopedia of Medicine. 2nd ed. Detroit, MI: Gale Group, 2001.
19. Low, Morris, Shigeru Nakayama, and Hitoshi Yoshioka. eds. Science, Technology and Society in Contemporary Japan. Cambridge, MA: Cambridge University Press, 1999.
20. Nakane, Chie. Japanese Society. Tokyo: Charles E. Tuttle, 1984.
21. Office of Pharmaceutical Industry Research. Syaku no ba to shite no Kysryoku Kyka ni Mukete [Strengthening Competitiveness, Developing Innovative Drugs]. Tokyo: Japan Pharmaceutical Manufacturers Association 2005.
22. Okimoto, Daniel I. Between MITI and the Market: Japanese Industrial Policy for High Technology. Stanford, CA: Stanford University Press 1989.
23. PJB Publications. Yearbook. Richmond: PJB, 1988, 1991, 2000.
24. -. Scrip: Pharmaceutical Company League Tables 2006. Richmond: PJB, 2006.
25. Seimei Hoken Bunka Sent?. Seimei Hoken ni Kansuru Zenkoku Jittai Chsa [National Survey on Life Insurance]. Tokyo: Seimei Hoken Bunka Sent? 1965-2009.
26. Shin NihonHki Shuppan. Yakka Kijun [Official Drug List]. Tokyo: Shin Nihon Hki Shuppan 1977-1990.
27. Suguro, Toshihiko. Iyakuin Gykai [The Pharmaceutical Industry]. Tokyo: Kyikusha, 1990.
28. Thomas, Lacey Glenn. The Japanese Pharmaceutical Industry: The New Drug Lag and the Failure of Industrial Policy. Northampton: Edward Elgar, 2001.
29. Urch Publishing. Cancer Market Trends, 2006-2010. London: Urch, 2006.
30. Vogel, Steven Kent. Japan Remodeled: How Government and Industry Are Reforming Japanese Capitalism. Ithaca, NY: Cornell University Press 2006.
31. Yakugy Jihsha. Yakuji Handobukku [Pharmaceutical Affairs Handbook]. Tokyo: Yakugy Jihsha 1968-1999.
32. Yakugy Keizai Kenkyjo. Yakugy Keizai Nenkan [Economics of the Pharmaceutical Industry Annual]. Tokyo: Yakuji Nippsha 1967, 1971, 1979, 1984, 1987.
33. Yakuji Nippsha. Saikin no Shinyaku [New Drugs in Japan]. Tokyo: Yakuji Nippsha 1950-2006.
34. Yano Research Institute. Iyakuhinshij Senryaku no tame no Mketingu Dta Nenp? [Marketing Data Annual for Strategizing in the Pharmaceutical Market]. Tokyo: Yano Research Institute, 1985.
35. -. Iyaku Sangy Nenkan [Pharmaceutical Industry Annual]. Tokyo: Yano Research Institute 1980-1985.
36. Anegawa, Tomofumi. "Nihon no Iyakuhin Sangy: Sono Seik to Shippai [The Japanese Pharmaceutical Industry: Its Success and Failure]." Iry to Shakai. 12, 2 (2002): 49-78.
37. Berndt, Ernst. "Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price." The Journal of Economic Perspectives. 16, 4 (2002): 45-66.
38. Centre for Medicines Research International. "Japan in Focus: Strategies for Innovation and Global Drug Development, What Differentiates Japanese Pharma Companies from Their Western Counterparts." R&D Briefing. 28 (1999): 1-8.
39. Collins, Steven, and Hikoji Wakoh. "Universities and Technology Transfer in Japan: Recent Reforms in Historical Perspective." The Journal of Technology Transfer. 25 (June 2000): 213-222
40. Danzon, Patricia, and Mark Pauly. "Health Insurance and the Growth in Pharmaceutical Expenditures." The Journal of Law and Economics. 45, s2 (2002): 587-613.
41. DeVita, Vincent, and Edward Chu. "A History of Cancer Therapy." Cancer Research. 68, 21 (2008): 8643-8653
42. Elwy, Todd S., Michael D. Fetters, Daniel W. Gorenflo, and Tsukasa Tsuda. "Cancer Disclosures in Japan: Historical Comparisons, Current Practices." Social Science & Medicine. 46 (September 1998): 1151-1163
43. End, Hisao, Matsur Oka, Masak Ozawa, Yoshiaki Kamoya, and Nobuo Tanaka. "Iryy Iyakuhin Shij ni Okeru Kys Keitai [Forms of Competition in the Ethical Pharmaceutical Market]." In Iyakuhin Sangy Soshikiron [On the Organization of the Pharmaceutical Industry], edited by Nanbu T. Tokyo: University of Tokyo Press. 49-74.
44. Feldman, Eric. "Medical Ethics the Japanese Way." The Hastings Center Report. 15, 5 (1985): 21-24
45. Fukushima, Masanori. "The Overdose of Drugs in Japan." Nature. 342, 21 (1989): 850-851
46. Futaba, Kunihiko. "Sengo no Iyakuhin Rytsshi: Kaj Seisan ni Taisuru Shij no Kakudai to Tsei no Hsaku [The History of Distribution in the Pharmaceutical Industry: Strategies for Controlling a Market Expanding with Overproduction]." Iyaku Jnaru. 11 (1972): 59-70.
47. Ikeo, Kyichi. "Iyakuhin Mk no Ryts Chaneru Seisaku [Firm Policies in Pharmaceutical Distribution]." Iyakuhin Rytsron, edited by Kataoka Ichir, Mitsuaki Shimaguchi, and Mimura Yumiko Tokyo: University of Tokyo Press. 85-112.
48. Kneller, Robert. "Autarkic Drug Discovery in Japanese Pharmaceutical Companies: Insights into National Differences in Industrial Innovation." Research Policy. 32 (2003): 1805-1827
49. Koinuma, Nobuo. "Gan Iry no Keizaiteki Hyka [Economic Evalutaion of Cancer Treatments]." Ksh Eisei. 71, 2 (2007): 108-112
50. Kreuger, Anne. "The Political Economy of the Rent-seeking Society." American Economic Review. 64 (1974): 291-303.
51. Laubach, Gerald D. "Federal Regulation and Pharmaceutical Innovation." Proceedings of the Academy of Political Science. 33, 4 (1980): 60-80.
52. Lieberman, Marvin B., and David B. Montgomery "First-mover Advantages." Strategic Management Journal. 9, 1 (1988): 41-58.
53. Lieberman, Marvin B., and David B. Montgomery "First-mover (Dis)advantages: Retrospective and Resource-based View." Strategic Management Journal. 19, 12 (1998): 1111-1125
54. Lipartito, Kenneth. "Culture and the Practice of Business History." Business and Economic History. 24, 2 (1995): 1-40.
55. Miyamoto, Mamoru. "Kongo Shinsatsu ni Tsuite [On Mixed Billing]." Kansai Daigaku Keizai-kei. 226 (2006): 77-85.
56. Nagasaka, Kenjir. "Nihon no Yakka Seido: Sono Mekanizumu to Impurikshon [Pharmaceutical Pricing in Japan: Its Mechanisms and Implications]." Osaka Keidai Ronsh. 57, 1 (2006): 71-96.
57. Nakao, Isao, Tadashi Yokoyama, Ichir Urushizaki, Akira Wakui, Hisashi Furue, Yoshiyuki Koyama, Kiyoji Kimura, Nobuya Ogawa, and Tatsuo Sait. "Shink Igan ni Taisuru PSK no Rinsh Kka [Clinical Effects of PSK in Advanced Gastric Cancer]." Oncologia. 14 (1985): 163-170
58. Nakayama, Shigeru, and Morris Low. "The Research Function of Universities in Japan." Higher Education. 34 (1997): 245-258
59. Nakamura, Yoshiaki, and Hiroyuki Odagiri. "Nihon no Baio Bench Kigy: Sono Igi to Jittai [Bio Ventures in Japan: Their Significance and Current Status]." REITI Discussion Paper. 02-J-007 (2002): 1-47.
60. Niimoto, MinoruTakao Hattori, Ryichiro Tanida, Koyoshi Inokuchi, and Nobuya Ogawa. "Igan Chiyu Setsujo Shrei ni Taisuru Maitomaishin C, Futorafru, Kuresuchin o Mochiita Jutsugo Men'eki Kagaku Ryh [Postoperative Immunotherapy for Curatively Resected Gastric Cancer Patients Using Mitomycin C, Ftorafur and Krestin]." Oncologia. 14 (1985): 171-180
61. Okamoto, H., M. Minami, S. Shoin, S. Koshimura, and R. Shimizu "Experimental Anticancer Studies Part XXXI. On the Streptococcal Preparation Having Potent Anticancer Activity." Japanese Journal of Experimental Medicine. 36 (1966): 175-186
62. Okamoto, Hajime, Susumu Shoin, Saburo Koshimura, and Ryusaku Shimizu. "Studies on the Anticancer and Streptolysin S-Forming Abilities of Hemolytic Streptococci." Japanese Journal of Microbiology. 11, 4 (1967): 323-326
63. Okamoto, H., S. Shoin, M. Minami, S. Koshimura, and R. Shimizu "Experimental Anticancer Studies Part XXX. Factors Influencing the Streptolysin S-forming Ability of Streptococci Having Anticancer Activity." Japanese Journal of Experimental Medicine. 36 (1966): 161-174
64. Reich, Michael. "Why the Japanese Don't Export More Pharmaceuticals: Health Policy as Industrial Policy." California Management Review. 32, 2 (1990): 124-150
65. Steslicke, William E. "Doctors, Patients, and Government in Modern Japan." Asian Survey. 12, 11 (1972): 913-931
66. Sugimura, Takashi. "Gankenky ni Kansuru Shomondai to Shohansei [Comments on Cancer Research in Japan]." Tanpakushitsu Kakusan Kso. 23, 6 (1978): 685-691
67. Swinbanks, David. "Japanese Doctors Keep Quiet." Nature. 339 (1989): 409.
68. -. "Japan's Foundations Still Building." Nature. 361 (1993): 761-764
69. Thomas, Lacey Glenn. "Spare the Rod and Spoil the Industry: Vigorous Competition and Vigorous Regulation Promote Global Competitive Advantage: A Ten Nation Study of Government Industrial Policies and Corporate Pharmaceutical Competitive Advantage." First Boston Working Paper Series. 90-03 (1990).
70. Ueda, Eiji. "Wagakuni no Chiken no Genj to Mondaiten [Current Situation and Issues regarding Clinical Trials in Japan]." Modan Media. 50, 2 (2004): 34-37
71. Umezawa, Hamao, Kenji Maeda, Tomio Takeuchi, and Yoshiro Okami. "New Antibiotics, Bleomycin A and B." Journal of Antibiotics, Series A. 19 (1966): 200-209
72. Wakaki, Shigetoshi. "Tsha ni Okeru Seiganzai no Kenky to Kaihatsu no Genj [The Status of Anticancer Drug R&D at our Company]." Kagakukgy. (1976): 96-98
73. Yongue, Julia. "Shinyaku Kaihatsu o Meguru Kigy to Gysei: Chiken o Chshin ni [Firms and Government in Drug Development: An Examination of Clinical Trials]." Kigy Bunseki to Gendai Shihon Shugi [Corporate Analysis and Contemporary Capitalism], edited by Kud A. and Ihara M. Kyoto: Minerva. (2008): 166-191
74. Yoshida, Tomiz. "Cancer Research in Japan." Cancer Research. 16, 11 (1956): 1007-1008
75. Aera. 1988.
76. Asahi Shimbun. 1976-1993.
77. Economist. 1983.
78. Financial Times. 1987.
79. Fortune. 1991.
80. Gekkan Mix. 1996.
81. Nikkei Business. 1985.
82. Shkan Shinch. 1991.
83. Chugai Pharmaceutical Co. Yka Shken Hkokusho [Annual Securities Report]. Tokyo: kurash Insatsukyoku, 1971, 1991.
84. -. Chgai Seiyaku 75-nen no Ayumi [A 75 year History of Chugai Pharmaceutical]. Tokyo: Chugai Pharmaceutical, 2000.
85. Kureha Chemical Industry Co. Kureha Kagaku 50-nenshi [A 50 Year History of Kureha Chemical Industry]. Tokyo: Kureha Chemical Industry 1995.
86. -. Yka Shken Hkokusho [Annual Securities Report]. Tokyo: kurash Insatsukyoku 1976.
87. Sankyo Co. Sanky 80-nenshi [Sankyo, A 80 year History]. Tokyo: Sankyo, 1979.
88. -. Yka Shken Hkokusho [Annual Securities Report]. Tokyo: kurash Insatsukyoku 1991.
89. Zeria Pharmaceutical Co. Enkaku [Company History]. Zeria Pharmaceutical Co.. http://www.zeria.co.jp/comp/co01.html (accessed December 1, 2007).
90. -. Yka Shken Hkokusho [Annual Securities Report]. Tokyo: kurash Insatsukyoku 1990.
91. "General Headquarters, Supreme Commander for the Allied Powers, Public Health and Welfare Section." Public Health and Welfare in Japan. Annual Summary: 1949. Tokyo: Supreme Commander for the Allied Powers. Public Health and Welfare Section, 1949.
92. "Japan, House of Councillors, Health and Welfare Committee." Official Report of Debates. 1980, 1981, 1993.
93. "Japan, House of Representatives, Health and Welfare Committee." Official Report of Debates. 1981, 1986, 1993.
94. Ministry of Education. Kyiku Shihy no Kokusai Hikaku [International Comparison of Education Benchmarks]. Tokyo: Office of the Prime Minister 1985-2005.
95. Ministry of Health and Welfare. Jink Dtai Shakai Keizaimen Chsa [Social and Economic Study of Vital Statistics]. Tokyo: Ministry of Health and Welfare 1994.
96. -. Kanja Chsa [Patient Survey]. Tokyo: Ministry of Health and Welfare 1953-1985.
97. -. Yakuji Kgy Seisan Dtai Chsa Tkei [Annual Survey on Production in the Pharmaceutical Industry]. Tokyo: Yakugy Keizai Kenkyjo 1953-2000.
98. Ministry of Health, Labour and Welfare. Deaths by Leading Cause of Death, Population and Households. http://www.stat.go.jp/english/data/chouki/ 02.htm (accessed December 1, 2007).
99. Ministry of International Trade and Industry. Tssh Hakusho [White Paper on Trade]. Tokyo: Gysei 1974-2000.
100. National Science Foundation (United States). Survey of Industrial Research and Development Historical Database. 1953-1998, http://www.nsf.gov/ statistics/iris (accessed November 13, 2009).
101. Office of the Prime Minister, Bureau of Statistics. Kagaku Gijutsu Kenky Chsa Hkoku [Report on the Survey of Research and Development]. Tokyo: Office of the Prime Minister 1961-1984.
102. U.S. Census Bureau. Scientific Research and Development Services 2002. Washington, DC: U.S. Census Bureau. http://www.census.gov/prod/ec02/ ec0254i07.pdf (accessed November 22 2009).
103. Yakugy Keizai Kenkyjo. Yakuji Nenkan [Pharmaceutical Affairs Annual]. Tokyo: Nihon Yakugy Shimbunsha 1951, 1957, 1961, 1964.
104. -. Yakugy Keizai Nenkan [Economics of the Pharmaceutical Industry Annual]. Tokyo: Yakuji Nippsha 1967, 1971, 1979, 1984, 1987.
105. Yakuji, Kenkykai. Saikin no Yakumu Gysei [Recent Trends in Pharmaceutical Administration]. Tokyo: Yakumu Khsha 1991.
106. American Board of Medical Specialties 2008 ABMS Certificate Statistics. http://www.abms.org/ (accessed April 9 2010).
107. Japanese Board of Cancer Therapy. Ninteii Seido Kisoku [Certified Oncologist egulations]. http://www.jbct.jp/sys-regulation01.html (accessed November 30 2007).
108. Japanese Society of Medical Oncology. Nihon Rinsh Shuy Gakkai Gan Yakbutsu Ryh Senmon'i Ninteisha [JSMO Medical Oncology Certificate List]. http://jsmo.umin.jp/senmoni/lists.html (accessed April 9 2010).
109. National Cancer Institute. What is Cancer? http://www.cancer.gov/ cancertopics/ what-is-cancer (accessed July 10, 2008).
110. National Health Service. Medical and Dental staff 2008 Detailed Results. http://www.ic.nhs.uk/statistics-and-data-collections/workforce/nhs-staffnumbers/ nhs-staff-1998-2008-medical-and-dental (accessed April 10, 2010).
111. Nippon Medical School. Research Institute of Vaccine Therapy for Tumors and Infectious Diseases, "Maruyama Vaccine". http://vaccine.nms.ac.jp/ (accessed December 1, 2007).